Low Diagnostic Accuracy of Tumor Markers for the Annual Screening of Pancreatic Neuroendocrine Tumors in MEN-1 Patients

#442

Introduction: The use of tumor markers for annual screening for pancreatic neuroendocrine tumors (pNET) in Multiple Endocrine Neoplasia type 1 (MEN-1) is debatable because of low-level evidence and high costs.

Aim(s): To assess the diagnostic accuracy of measuring Chromogranin A (CgA), pancreas polypeptide (PP) and glucagon for the annual screening for pNET in MEN-1.

Materials and methods: In the period 2008-2010 a cross-sectional study was performed as part of the retrospective nationwide Dutch MEN-1 database. The area under the receiver operating characteristics (ROC) curves (AUC) of CgA, PP and glucagon were calculated with an AUC of 0.60-0.80 indicating moderate and 0.80-1.00 indicating good diagnostic accuracy. The gold standard for pNET detection was pathology and if unavailable, detection on MRI, CT or EUS with confirmation at least once on subsequent imaging. For CgA only patients without lung- and thymus NET and those not using PPI were included in the analysis.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: De Laat J, Weijmans M, Hermus A, Dekkers O, De Herder W,

Keywords: MEN-1, tumor marker, annual screening, Chromogranin A,